Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review.
Fakih
Marwan
M
Department ofMedicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Johnson
Candace S
CS
Trump
Donald L
DL
D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism; D000726:Androgen Antagonists / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D017302:Annexins / Q000187:drug effects / Q000378:metabolism; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D005938:Glucocorticoids / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D012189:Retrospective Studies; D014158:Transcription, Genetic / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000187:drug effects / Q000378:metabolism; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
D000726:Androgen Antagonists; D017302:Annexins; D018931:Antineoplastic Agents, Hormonal; D005938:Glucocorticoids; D016212:Transforming Growth Factor beta